MARKET

KALA

KALA

Kala Pharmaceuticals Inc
NASDAQ
4.240
-0.385
-8.32%
After Hours: 4.290 +0.05 +1.18% 16:16 04/04 EDT
OPEN
4.630
PREV CLOSE
4.625
HIGH
4.630
LOW
4.010
VOLUME
35.54K
TURNOVER
--
52 WEEK HIGH
11.20
52 WEEK LOW
4.010
MARKET CAP
27.36M
P/E (TTM)
-0.4179
1D
5D
1M
3M
1Y
5Y
1D
KALA BIO Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
Kala Pharmaceuticals: Promising Clinical Developments and Financial Stability Support Buy Rating
TipRanks · 2d ago
Kala Pharmaceuticals management to meet with Oppenheimer
TipRanks · 4d ago
KALA BIO Advances Eye Disease Therapies with New Funding
TipRanks · 6d ago
Kala Bio Q4 EPS $(1.74) Beats $(2.28) Estimate
Benzinga · 6d ago
Kala Pharmaceuticals reports Q4 EPS ($1.74) vs. ($3.18) last year
TipRanks · 6d ago
Kala Pharmaceuticals sees cash runway into 1Q26
TipRanks · 6d ago
*KALA BIO Cash Resources of $51.2M as of Dec 31 Expected to Fund Ops Into 1Q 2026 >KALA
Dow Jones · 6d ago
More
About KALA
More
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
Recently
Symbol
Price
%Change

Webull offers KALA BIO Inc stock information, including NASDAQ: KALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KALA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KALA stock methods without spending real money on the virtual paper trading platform.